Tokyo, September 30, 2021 — FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) has reached agreement on core terms with Australian regenerative medicine venture Cynata Therapeutics Limited (Cynata) to manufacture regenerative medicine products using induced pluripotent stem (iPS) cells. Based on the core terms, Fujifilm will conduct clinical and commercial manufacturing for Cynata’s pipeline….
Cambridge, Mass., and Madison, Wis. [May 17, 2021] – BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics (FCDI) and David Gamm, M.D.,….
FUJIFILM Cellular Dynamics, Inc. and Sana Biotechnology, Inc. announced today that Sana has been granted a non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development of commercial cell therapies.
FUJIFILM Cellular Dynamics grants Lonza a non-exclusive right to use their patents related to iPSC generation, including episomal vectors and reprogramming factors, for development and clinical manufacture of iPSC lines for cell therapies Lonza grants FUJIFILM Cellular Dynamics expanded use of its non-exclusive license to its innovative Nucleofector™ technology The agreement enables drug developers to….
MILAN (Italy) and MADISON (Wis., USA) – October 6, 2020 – Axxam S.p.A., a leading provider of integrated drug discovery services across life sciences industries, and FUJIFILM Cellular Dynamics, Inc., a leading developer and manufacturer of human induced pluripotent stem cell (hiPSC) models and therapies, announce a strategic alliance to improve the drug discovery process…..